Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy
Top Cited Papers
- 31 August 2009
- journal article
- review article
- Published by Wiley in Photochemistry and Photobiology
- Vol. 85 (5), 1053-1074
- https://doi.org/10.1111/j.1751-1097.2009.00585.x
Abstract
Photodynamic therapy (PDT) is now a well‐recognized modality for the treatment of cancer. While PDT has developed progressively over the last century, great advances have been observed in the field in recent years. The concept of dual selectivity of PDT agents is now widely accepted due to the relative specificity and selectivity of PDT along with the absence of harmful side effects often encountered with chemotherapy or radiotherapy. Traditionally, porphyrin‐based photosensitizers have dominated the PDT field but these first generation photosensitizers have several disadvantages, with poor light absorption and cutaneous photosensitivity being the predominant side effects. As a result, the requirement for new photosensitizers, including second generation porphyrins and porphyrin derivatives as well as third generation photosensitizers has arisen, with the aim of alleviating the problems encountered with first generation porphyrins and improving the efficacy of PDT. The investigation of nonporphyrin photosensitizers for the development of novel PDT agents has been considerably less extensive than porphyrin‐based compounds; however, structural modification of nonporphyrin photosensitizers has allowed for manipulation of the photochemotherapeutic properties. The aim of this review is to provide an insight into PDT photosensitizers clinically approved for application in oncology, as well as those which show significant potential in ongoing preclinical studies.Keywords
This publication has 102 references indexed in Scilit:
- Photodynamic Molecular Beacon Triggered by Fibroblast Activation Protein on Cancer-Associated Fibroblasts for Diagnosis and Treatment of Epithelial CancersJournal of Medicinal Chemistry, 2008
- Encapsulation of methylene blue in polyacrylamide nanoparticle platforms protects its photodynamic effectivenessBiochemical and Biophysical Research Communications, 2008
- Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: The case experience with preclinical mechanistic and early clinical–translational studiesToxicology and Applied Pharmacology, 2007
- The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and menCancer Chemotherapy and Pharmacology, 2006
- Photodynamic therapy and anti-tumour immunityNature Reviews Cancer, 2006
- Photodynamic damage by liposome-bound porphycenes: comparison between in vitro and in vivo modelsJournal of Photochemistry and Photobiology B: Biology, 1998
- The Shape of Cell DeathBiochemical and Biophysical Research Communications, 1997
- Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumours of miceJournal of Photochemistry and Photobiology B: Biology, 1995
- A pilot study of photodynamic therapy in patients with inoperable non-small cell lung cancerEuropean Journal of Cancer, 1992
- The toluidine blue test: An aid in the diagnosis and treatment of early squamous cell carcinomas of mucous membranesJournal of the American Academy of Dermatology, 1988